%0 Journal Article
%T A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study
%A Paola Zavarise
%A Giorgio Dalla Volta
%J Open Access Library Journal
%V 4
%N 6
%P 1-9
%@ 2333-9721
%D 2017
%I Open Access Library
%R 10.4236/oalib.1103660
%X
Background: effective
treatments for migraine aura and related symptoms are not yet well established.
In the last years, several herbal and/or nutraceutical preparations have been proposed as potential
treatment. We report the results of a retrospective analysis on the synergistic
effect of three nutraceutical components (Tanacetum parthenium, Griffonia simpliciofila and
Magnesium, Aurastop) as symptomatic treatment of migraine aura and related
symptoms. Method: Forty-nine subjects with headache with aura were recruited
from the headache Center of the Istituto Clinico
Citta¡¯ di Brescia to enter the studied that consist
to treat the first 3 aura attacks as usual and the next 3 taking a tablet of Aurastop
at the beginning of the aura phenomena. They had to describe aura and headache
characteristics of previous three attacks (t1) and the modification of these
parameters with the assumption of Aurastop for the following three attacks
(t2). Results: A significant reduction (>50%) in aura duration (t1 = 33.6 ¡À 10.1 minutes vs. t2 = 9.4 ¡À 6.2 minutes, p < 0.01
FWER corrected) as well as in overall disability (median [interquartile range]) (t1 = 5[4 - 5] vs. t2 = 1[1 - 2], p < 0.01 FWER corrected) was evident. Furthermore,
modification of aura type as well as a series of parameters more related to
headache (number of headache attacks, duration, intensity, utilization of
analgesics and response to symptomatic treatment) was influenced by Aurastop utilization (p < 0.01 FWER corrected). No
significant adverse effects were recorded after the assumption of Aurastop. Conclusions:
the combined and synergistic effect of Tanacetum parthenium, Griffonia simpliciofila and
Magnesium (Aurastop) highlights the idea that symptomatic treatment
potentially modulating cortical spreading depression could deserve attention to
mitigate aura and related symptoms (migraine as well as long-lasting
discomfort). Further blinded, placebo-controlled studies on larger groups are
warranted.
%K Migraine Aura
%K Cortical Spreading Depression
%K NMDA Receptor
%U http://www.oalib.com/paper/5286353